T32 DA007209/DA/NIDA NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2007	1
2008	6
2009	7
2010	6
2011	16
2012	15
2013	18
2014	28
2015	21
2016	27
2017	36
2018	32
2019	35
2020	53
2021	38
2022	17

1

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Davis AK, et al. JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285. JAMA Psychiatry. 2021. PMID: 33146667 Free PMC article. Clinical Trial.

2

Long-term follow-up of psilocybin-facilitated smoking cessation.

Johnson MW, Garcia-Romeu A, Griffiths RR. Johnson MW, et al. Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60. doi: 10.3109/00952990.2016.1170135. Epub 2016 Jul 21. Am J Drug Alcohol Abuse. 2017. PMID: 27441452 Free PMC article. Clinical Trial.

3

A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.

Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. Luoma JB, et al. J Psychoactive Drugs. 2020 Sep-Oct;52(4):289-299. doi: 10.1080/02791072.2020.1769878. Epub 2020 Jun 12. J Psychoactive Drugs. 2020. PMID: 32529966 Free PMC article.

4

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Johnson MW, et al. J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11. J Psychopharmacol. 2014. PMID: 25213996 Free PMC article. Clinical Trial.

5

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Garcia-Romeu A, Griffiths RR, Johnson MW. Garcia-Romeu A, et al. Curr Drug Abuse Rev. 2014;7(3):157-64. doi: 10.2174/1874473708666150107121331. Curr Drug Abuse Rev. 2014. PMID: 25563443 Free PMC article. Clinical Trial.

6

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Gukasyan N, et al. J Psychopharmacol. 2022 Feb;36(2):151-158. doi: 10.1177/02698811211073759. J Psychopharmacol. 2022. PMID: 35166158 Free PMC article. Clinical Trial.

7

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.

Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. Davis AK, et al. Am J Drug Alcohol Abuse. 2019;45(2):161-169. doi: 10.1080/00952990.2018.1545024. Epub 2019 Mar 1. Am J Drug Alcohol Abuse. 2019. PMID: 30822141 Free PMC article.

8

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR. Carbonaro TM, et al. J Psychopharmacol. 2016 Dec;30(12):1268-1278. doi: 10.1177/0269881116662634. Epub 2016 Aug 30. J Psychopharmacol. 2016. PMID: 27578767 Free PMC article.

9

Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl.

Varshneya NB, Thakrar AP, Hobelmann JG, Dunn KE, Huhn AS. Varshneya NB, et al. J Addict Med. 2021 Nov 23:10.1097/ADM.0000000000000922. doi: 10.1097/ADM.0000000000000922. Online ahead of print. J Addict Med. 2021. PMID: 34816821

10

Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.

Yaden DB, Johnson MW, Griffiths RR, Doss MK, Garcia-Romeu A, Nayak S, Gukasyan N, Mathur BN, Barrett FS. Yaden DB, et al. Int J Neuropsychopharmacol. 2021 Aug 20;24(8):615-623. doi: 10.1093/ijnp/pyab026. Int J Neuropsychopharmacol. 2021. PMID: 33987652 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results